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need to undergo surgery should also undergo preoperative 
evaluation by an expert cardiologist. Treatment with long-
acting somatostatin analogs aims at controlling the exces-
sive hormonal output and symptoms related to the carci-
noid syndrome and at preventing a carcinoid crisis during 
interventions. Patients with a gastrinoma require pre- and 
postoperative treatment with high doses of proton pump 
inhibitors. Patients with a glucagonoma require somatosta-
tin analog treatment and nutritional supplementation. Pa-
tients with a VIPoma also require somatostatin analog treat-
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 Abstract 
 Neuroendocrine tumors of the small intestine are the most 
common causes of the carcinoid syndrome. Carcinoid heart 
disease occurs in more than half of the patients with the car-
cinoid syndrome. Patients with carcinoid heart disease who 
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ment and intravenous fluid and electrolyte therapy. Insuli-
noma patients generally require intravenous glucose 
infusion prior to operation. In patients with localized oper-
able insulinoma, somatostatin analog infusion should only 
be considered after the effect of this therapy has been elec-
tively studied.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Preoperative Diagnostic Procedures 
 Prior to surgery or other interventional treatment in 
patients with neuroendocrine tumors (NET), the tumor 
type and hormone production must be assessed in order 
to provide appropriate treatments as well as to avoid life-
threatening crises that may occur due to the presence of 
hormonal syndromes associated with some of these tu-
mors  [1] . In addition, the presence of any triggering fac-
tors should be determined.
 A low threshold for further cardiac workup should be 
utilized in patients with the carcinoid syndrome, employ-
ing NT-proBNP measurements and echocardiography, 
or cardiac magnetic resonance imaging, since the report-
ed incidence of different grades of cardiac involvement 
could be as high as 50%  [2] . However, more recent studies 
suggest that the prevalence of carcinoid heart disease 
(CHD) has decreased during the last decades to about 
20%, probably due to the use of somatostatin analogs  [3] . 
 Carcinoid Syndrome: Pre- and Perioperative Therapy 
 Carcinoid Syndrome 
 NET of the small intestine are the most common 
causes of the carcinoid syndrome that occurs in 20–30% 
of patients with liver metastases from these NET. The 
classical (typical) carcinoid syndrome is usually charac-
terized by cutaneous flushing, gut hypermobility with di-
arrhea and bronchospasm with wheezing and shortness 
of breath  [4] . The syndrome is occasionally also encoun-
tered in patients with large lymph nodes, peritoneal, 
ovarian lesions (primary or metastases) or bronchial car-
cinoids, where secretory products exceed the capacity of 
inactivation by the liver, or bypass the liver being released 
directly into the systemic circulation  [5, 6] . Preoperative-
ly, patients with small intestinal NET need to be carefully 
evaluated and treated for manifestations of the carcinoid 
tumor, paying particular attention to reveal previously 
unnoticed diarrhea or flushing, and incipient CHD, and 
in such cases protective actions should be taken to pre-
vent a carcinoid crisis during surgery  [7, 8] . Patients with 
or without carcinoid syndrome may present with large 
desmoplastic fibrotic reactions of the peritoneum usually 
around the involved lymph nodes, which may cause ob-
structive associated symptoms.
 Preoperative Fluid Electrolyte, Vitamin, and Protein 
Abnormalities 
 Diarrhea in patients with carcinoid syndrome may 
cause dehydration, electrolyte abnormalities, and hypo-
proteinemia  [7, 8] . In the presence of carcinoid syndrome, 
the essential amino acid tryptophan is converted to sero-
tonin, leaving inadequate amounts of tryptophan for con-
version to niacin and proteins, which contributes to hy-
poproteinemia  [8] . Niacin deficiency may cause pellagra, 
with dermatitis, diarrhea, and dementia  [9] . In addition, 
deficiencies of other fat-soluble vitamins, following prior 
treatment with somatostatin analogs, should be looked 
for and adequately substituted  [10] . Patients with severe 
diarrhea, weight loss and hypoproteinemia require par-
enteral nutrition with adequate supplementation before 
surgery is undertaken.
 Carcinoid Heart Disease 
 CHD occurs in more than half of the patients with car-
cinoid syndrome, with serotonin being an important me-
diator  [11–13] . However, it can remain undiagnosed as 
shown in a recent study of 150 patients with carcinoid 
syndrome, of whom 37% with CHD exhibited no physical 
signs  [14] .
 Fibrotic plaques affect the valves and cavities of the 
right ventricle, with thickening of valvular leaflets and 
shortening of the chordae tendineae, resulting in tricus-
pid regurgitation and pulmonary stenosis. Tricuspid 
valves have been affected in 95% of patients, while pulmo-
nary valves have been less frequently involved. Left-sided 
valvular lesions are rare because mediators are cleared or 
inactivated in the lungs before reaching the left side of the 
heart, but can occur due to patent foramen ovale, lung 
tumors or overwhelming disease. Concomitant mitral 
and aortic regurgitation has occasionally been demon-
strated  [12, 13] . A 5-hydroxyindoleacetic acid (5-HIAA) 
level of  ≥ 300 μmol/24 h and  ≥ 3 episodes of flushing per 
day are considered to be independent predictors of the 
development or progression of CHD  [3] . It has recently 
been suggested that plasma 5-HIAA measurements could 
also serve as an additional tumor marker that could po-
tentially ameliorate the need of urinary 5-HIAA measure-
ments  [15] .
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 Diagnosis of CHD is difficult, and cardiac symptoms 
do not appear until late stages of the disease. Diagnosis of 
CHD requires 2-dimensional echocardiography and 
Doppler examination to assess the severity of valvular ste-
nosis and regurgitation (CHD guidelines)  [13] . More-
over, NT-proBNP has been shown to exert a high sensi-
tivity and specificity (87 and 80%, respectively) in pre-
dicting CHD and it has also been shown to correlate with 
patient survival  [16] . Severe tricuspid regurgitation also 
strongly correlates with poor survival in patients with car-
cinoid syndrome.
 In patients with carcinoid valvular heart disease, mor-
bidity from abdominal operation is markedly increased. 
CHD poses 2 distinct challenges for the anesthesiologist: 
carcinoid crisis and low cardiac output syndrome second-
ary to right ventricular failure  [17] . Patients may have in-
cipient cardiac failure and be poor candidates for surgery, 
or they may fail to recover after operation. Moreover, 
right-sided heart failure increases central venous pressure 
and may markedly increase the risk of bleeding, from he-
patic veins, especially during liver surgery  [13] . Echocar-
diography should be done in all patients with the carcinoid 
syndrome, and patients with moderate CHD should al-
ways be discussed with cardiologists before surgery. In 
case of significant heart disease, a cardiothoracic surgical 
evaluation and possible surgical valvular replacement may 
be required before major abdominal operation  [13, 17, 18] .
 Reconstructive valve replacement surgery has been re-
ported to be of obvious value for patients with advanced 
heart disease and right ventricular failure, with low mor-
tality in young patients but high risk in patients older than 
60 years of age  [11, 19, 20] . However, in a recent meta-
analysis, age was not found to be a contributing factor of 
higher mortality  [21] . During cardiac surgery, risks for 
carcinoid crisis may be high because patients often re-
quire vasoactive medication to support the circulatory 
system, which may trigger carcinoid crisis  [2] . In a series 
of 22 patients who underwent valve replacement, 4 died 
within 30 days postoperatively and in 1 of them carcinoid 
crisis was the main cause of death  [3] . There is still con-
troversy regarding the use of vasoconstrictor amines in 
case of hypotension as there are several reports in favor 
of and against their use  [7, 8, 19] . However, approximate-
ly 90% of 11 patients who underwent valvular replace-
ment and received inotropic agents to wean them off, car-
diopulmonary bypass did not experience any symptom-
atic exacerbation while being on concomitant octreotide 
cover  [17] . In addition, patients pretreated with long-act-
ing somatostatin analogs required higher doses of octreo-
tide infusions (median 320 vs. 750 μg)  [17] . 
 Carcinoid Crisis 
 Patients with carcinoid syndrome are at risk for devel-
oping a carcinoid crisis during either minor or major  sur-
gery or other types of intervention, such as arterial embo-
lization, radiofrequency ablation, endoscopic procedures, 
diagnostic procedures or treatment with peptide receptor 
radionuclide therapy  [7, 8, 22–25] . The presence of CHD 
and high 5-HIAA levels have been shown to represent 
predictors of an emerging carcinoid crisis  [26] . Patients 
undergoing such procedures or minor operations should 
be carefully assessed for the presence of such risks and 
relevant therapeutic interventions should be utilized if re-
quired.  The crisis may also be provoked by severe emo-
tional stress, induction of anesthesia during ravage of the 
abdomen, or as a result of tumor manipulation or tumor 
necrosis during surgery or intervention  [27] .
 Patients with carcinoid crisis may have sudden chang-
es in blood pressure, most often hypotension, sometimes 
combined with prolonged and excessive flushing, hyper-
thermia, and occasional bronchospasm. Some may have 
attacks of hypertension and occasional hypertensive cri-
sis due to tumor release of catecholamines  [28–30] . Pa-
tients with large tumor load, high chromogranin A levels, 
or high urinary 5-HIAA values are more likely to experi-
ence a carcinoid crisis during surgery; however, not all of 
these risk factors have consistently been confirmed  [2] . 
Catecholamines released from the adrenals or sympathet-
ic neurons are thought to contribute to the release of tu-
mor products, and thus appropriate pain relief can reduce 
the stress response  [7, 8, 27] . This is particularly impor-
tant as intraoperative hypotension may occur in both 
functioning and apparently nonfunctioning tumors with 
the most important predictor being the presence of he-
patic metastases  [27] .
 Sometimes the crisis complication presents with 
vague symptoms, and patients continue to be unstable 
postoperatively, or fail to recover after surgery, which 
emphasizes the importance of being aware of an undiag-
nosed carcinoid crisis, possibly reversible with appropri-
ate treatment  [31] . Previous treatment with long-acting 
somatostatin analogs aims at controlling the excessive 
hormonal output and symptoms related to the carcinoid 
syndrome and prevent a carcinoid crisis. In some cases, 
addition of ondansetron may help control the diarrhea 
 [32] .
 The ideal scheme and dosing of octreotide to prevent 
the development of a carcinoid crisis have not been clear-
ly established  [27, 31] . Acute intravenous administration 
of octreotide has been reported to provide rapid reversal 
of a carcinoid crisis, and the current focus of carcinoid 
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therapy is to prevent mediator release with octreotide 
prophylaxis  [2, 7, 8, 18, 22, 26, 31] . This has largely re-
placed the use of other drugs for acute treatment. If pa-
tients already receive long-acting somatostatin analogs, 
these medications should continue. However, as intraop-
erative carcinoid events are not easily predicted, there is 
no standard octreotide administration regimen and vari-
ous schemes have been proposed  [2] . It has been suggest-
ed that for minor procedures or lower-risk patients, a rea-
sonable scheme is the subcutaneous administration of oc-
treotide 100–200 μg 2–3 times/day during surgery  [2] . 
However, as a carcinoid crisis can also be induced even 
with minor surgical procedures, intravenous octreotide 
infusions should also be readily available to be used when 
necessary. For elective intra-abdominal or other major 
operations, the administration of octreotide 100 μg 3 
times/day subcutaneously for 2 weeks has been suggested 
prior to surgery  [2, 33] . However, intravenous octreotide 
is currently considered the most preferable mode of ad-
ministration  [31] . With acute operations, octreotide is 
 beneficial even if given for only 24 h before surgery, since 
this may achieve adequate suppression of basal amine and 
peptide levels  [34] . However, a single dose of 500 μg of 
octreotide was shown not to be sufficient to inhibit peri-
operative complications as well as previous treatment 
with somatostatin analogs  [27] . Perioperative prophylac-
tic treatment with intravenous octreotide, at a starting 
dose of 50–100 μg/h (mean dose 100–200 μg/h) is cur-
rently used by most centers as an appropriate regimen 
and shown to successfully prevent crisis during major 
surgery with little side effects in some studies  [7, 8] . Al-
though this has not been substantiated by any prospective 
study, most experts initiate treatment with intravenous 
octreotide 12 h before escalating the dose as necessary 
until symptom control and continued at least 48 h after 
the operation with dose titration as required. Some pa-
tients may still have symptoms and require additional in-
travenous octreotide and doses up to 500 μg/h have been 
administered  [2, 31] . A study that formally assessed the 
efficacy of octreotide in preventing carcinoid crisis has 
found that intraoperative complications (e.g., flushing, 
sustained hypotension, bronchospasm, acidosis [pH 
<7.2], and ventricular tachycardia) developed in 11% of 
patients who did not receive the medication compared to 
none of those who received intraoperative octreotide ( p = 
0.023). In addition, a recent meta-analysis has suggested 
that patients pretreated with somatostatin analogs (main-
ly octreotide) may require even higher doses  [31] . How-
ever, although octreotide is of proven value in preventing 
and treating carcinoid crisis, the current literature relies 
on small sample size studies and relatively low quality of 
data. In addition, the inconsistent use of the term carci-
noid crisis and the paucity of reported articles preclude 
the adaption of a universally accepted octreotide dosing 
scheme  [2, 31] .
 Atypical Carcinoid Syndrome 
 A less common atypical carcinoid syndrome may be 
encountered in patients with tumors originating from the 
foregut including mostly the lung, but also the stomach 
and duodenum  [6, 35] . The syndrome consists of patchy, 
intensely red flush, sweating, itching, sometimes also cu-
taneous edema, bronchoconstriction, salivary gland 
swelling, lacrimation, and cardiovascular instability 
mainly manifested as hypotension  [6, 35] . It is usually en-
countered in patients with liver metastases and is due to 
the release of both histamine and serotonin. Patients with 
the atypical carcinoid syndrome have a  decarboxylation 
deficit and therefore only seldom have excess urinary ex-
cretion of the serotonin metabolite 5-HIAA  [6, 36] . Uri-
nary estimates of the histamine metabolite methylimid-
azole acetic acid may serve as a tumor marker  [22, 36] . 
Cytoreductive surgery or hepatic artery embolization 
may occasionally be contraindicated due to the risk of 
uncontrolled release reactions.
 In the presence of an atypical carcinoid syndrome, the 
patients should be treated with octreotide before and dur-
ing surgery or intervention  [6, 35] (see Atypical Carci-
noid Syndrome). Patients with the severest reactions (e.g., 
mainly patients with lung carcinoids) may require higher 
doses of octreotide (100–200 μg/h) and sometimes also 
saline infusion  [6, 35] . Histamine-liberating substances 
like morphine or tubocurarine and adrenergic drugs 
should be avoided during anesthesia as they may cause 
further histamine release and lead to the development of 
hypotension  [2] . Combination with H 1 receptor blockers 
(loratadine) and H 2 blockers (ranitidine) is recommend-
ed in the presence of severe symptoms, and sometimes 
also cortisone (dexamethasone), since histamine release 
and its peripheral actions may not be blocked by soma-
tostatin analogs  [6, 36] .
 Specific Recommendations Concerning Anesthesia 
 Premedication 
 Premedication is focused on relieving existing symp-
toms and preparing for a potential carcinoid crisis  [37] . 
All patients’ maintenance medications should be contin-
ued and benzodiazepines and antihistamines could be 
used to decrease anxiety and stress  [7] . Monitoring the 
central venous pressure may aid in fluid management, 
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but interpretation may be difficult in the presence of 
CHD with tricuspid regurgitation or pulmonary stenosis 
 [7, 8] . As rapid blood pressure changes are commonly 
encountered in such patients, invasive monitoring is typ-
ically required; it is started before the induction of anes-
thesia and maintained throughout the procedure  [2] . Ar-
terial catheter monitoring is considered for major surgery 
since the hypotension seen with induction agents may 
trigger a carcinoid crisis  [38] . Accurate airway pressure 
monitoring is necessary to rapidly detect the onset of 
bronchospasm whereas continuous temperature moni-
toring and warming devices are needed as hypothermia 
could trigger a carcinoid crisis  [2] .
 Drugs that stimulate the sympathetic nervous symp-
toms or cause histamine release such as morphine and 
 d -tubocurarine should be avoided  [33] . Propofol, thio-
pental sodium, and etomidate have been used to induce 
anesthesia. Propofol has a more profound effect in sup-
pressing catecholamine release and may be the best agent 
in patients with carcinoid syndrome as long as hypoten-
sion is avoided  [39] . Furthermore, only nondepolarizing 
neuromuscular blockers that do not cause histamine re-
lease should be used  [7] . Due to its cardiovascular stabil-
ity, vecuronium and rocuronium can be safely used  [2] . 
Safe use of succinylcholine has also been documented. 
During maintenance of anesthesia, special attention 
should be paid to avoid right ventricular overload and 
strain to prevent right ventricular failure and the develop-
ment of cardiovascular alterations that mostly present as 
blood pressure and heart rate instability rather than 
rhythm abnormalities  [2, 7] .
 Hypotension is the most common problem during an-
esthesia, but in this situation sympathomimetic drugs 
should be avoided, since they may worsen hypotension by 
triggering further release of peptides. However, this view 
is not widely accepted as several reports have shown that 
the use of inotropic agents along with octreotide can re-
store the cardiovascular instability  [2, 27] . Hypotension 
tends to occur when large bulky metastases are manipu-
lated and in such instances stopping the procedure until 
hemodynamic control is restored is a simple maneuver 
 [7, 8] . Intravenous octreotide can correct hypotension 
within 10 min and thereafter, and is used in combination 
with volume expanders.
 Hypertension is also treated by prevention of peptide 
release with octreotide, and by increasing the depth of 
anesthesia. Bronchospasm can occasionally be severe, 
and since β-receptor agonists and theophylline may pre-
cipitate mediator release and worsen bronchospasm, they 
should be used with extreme care  [7, 8] . Octreotide may 
be used for the release of bronchospasm, and steroids 
(dexamethasone) may still have a role in such patients. 
Flushing may occur and may in itself not be problematic 
but it is a warning of potential cardiovascular instability, 
and indicates increased requirement of octreotide. Re-
covery from anesthesia may also be substantially delayed 
 [27, 40] .
 Postoperative Period 
 Preoperative treatment with octreotide should contin-
ue and should cease slowly over the first postoperative 
week rather than stop abruptly. Hypovolemia and pain 
causing sympathetic stimulation should be avoided in the 
postoperative period. Non-histamine-releasing opioids 
such as fentanyl have been used with no adverse effects 
for postoperative analgesia. Endocarditis prophylaxis 
may be required if significant carcinoid-induced valvular 
heart disease is present, although this approach is still a 
matter of debate  [41] . Epidural and spinal anesthesia have 
been successfully used in patients with carcinoid tumors 
mainly undergoing noncarcinoid surgery  [42] . Care 
should be taken to evaluate and premedicate these pa-
tients adequately, as hypotension may commonly occur 
with these techniques  [2] .
 Pancreaticoduodenal NET: Pre- and Perioperative 
Therapy 
 Among patients with pancreaticoduodenal NET, pre-
operative and prolonged postoperative treatment with 
adequately high dosed proton pump inhibitors (PPIs) is 
needed for patients with gastrinoma mainly to prevent 
gastrojejunal bleeding, and perioperative glucose moni-
toring is used to avoid hypoglycemia in patients with in-
sulinoma. Patients with glucagonoma require somatosta-
tin analog treatment and nutritional supplementation to 
heal the skin lesion prior to surgery, and perioperative 
anticoagulation to prevent thrombosis. Patients with
VIPoma need to be resuscitated with preoperative soma-
tostatin analog treatment and intravenous fluid and elec-
trolyte therapy before being subjected to surgery  [1, 6] .
 In some studies, perioperative somatostatin or soma-
tostatin analog treatment has been demonstrated to result 
in a significant reduction in the pancreatic fistula rate af-
ter elective pancreatic surgery, without having an influ-
ence on postoperative mortality  [43] . Octreotide 100–200 
μg subcutaneously 3–4 times/day for 6–8 days may re-
duce the risk for fistulation and minimize leakage after a 
difficult resection or enucleation of endocrine pancreatic 
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tumors, but may not be routinely required. However, re-
cent prospective trials showed that such an approach had 
no effect  [44, 45] . If somatostatin has been used, it should 
be weaned slowly rather than discontinued abruptly. Pa-
tients subjected to splenectomy in association with re-
moval of an endocrine pancreatic tumor are given vacci-
nations against meningococcus and  Haemophilus influ-
enza  and Pneumovax the day prior to hospital discharge 
to prevent postsplenectomy sepsis.
 Gastrinoma 
 Gastrinomas are predisposed to gastrointestinal per-
foration and hemorrhage, which may cause death after 
pancreaticoduodenectomy. During and 3 months after 
surgery, patients need adequately high doses of PPIs to 
efficiently control the acid hypersecretion that persists 
even after removal of the primary tumor mainly by re-
sidual hypertrophy of gastric mucosa  [46] . The dose of 
antisecretory drug is titrated to reduce the acid hyperse-
cretion to  ≤ 10 mEq/h, or to lower values in patients with 
previous acid-reducing surgery or severe reflux disease. 
High initial doses of PPIs (such as 60–80 mg/day of 
omeprazole) are frequently prescribed, with dose adjust-
ment as necessary based on symptom response. In the 
acute setting where oral medications may be contraindi-
cated, intravenous formulations are effective. A starting 
dose of 80 mg of pantoprazole given by a 15-min infusion 
every 8 h was recommended because it controlled gastric 
acid hypersecretion in all Zollinger-Ellison syndrome 
patients studied both acutely and up to 7 days  [47] . How-
ever, many specialized pancreatic centers preconize to 
treat patients with high doses of PPIs following 1–3 
months after pancreaticoduodenectomy. Octreotide can 
be used to treat Zollinger-Ellison syndrome but it does 
not add significantly to the acid-reducing effect of PPIs, 
which is the preferred medication  [48] . Patients should 
maintain their medication with PPIs for some weeks af-
ter surgery since many continue to hypersecrete acid for 
some time  [49] .
 Insulinoma 
 Preoperative diazoxide treatment is sometimes used to 
control hypoglycemia prior to operation, but may cause 
severe fluid retention and edema in some patients. It is 
generally not recommended prior to surgery for benign 
insulinoma. Patients with insulinoma and significant hy-
poglycemia should preferably be submitted to surgery 
without delay, and without diazoxide. At times of hypo-
glycemia, dextrose administration, intramuscular gluca-
gon, and potassium replacement may be required as a res-
cue procedure.  Patients with severe hypoglycemia may 
require intravenous glucose infusion on the night prior to 
operation to avoid risk of unrecognized hypoglycemia 
 [50] . In the operating room, glucose is removed from the 
intravenous solution to allow glucose monitoring with a 
rise in glucose anticipated within minutes to an hour after 
insulinoma resection  [50] . Small doses of insulin may be 
required during the first postoperative days. After surgery 
for large insulinomas, patients may need glucose infusion 
as insulin effects may still prevail for some time, and 
blood glucose levels should be monitored. Preoperative 
octreotide infusion should only be considered after the 
effect of this therapy is electively studied. In some insuli-
noma patients, octreotide infusion might lead to more 
severe hypoglycemias by suppression of the contraregula-
tory hormones. It is claimed that only in half of the non-
metastatic or benign insulinomas might octreotide have 
a positive effect  [51] .
 Glucagonoma 
 Glucagonoma patients may have troublesome skin 
disease and some patients may be cachectic. Somatostatin 
analog treatment, amino acid infusion, and antibiotics 
may improve the condition and heal the skin lesion be-
fore surgery  [52] . Patients have substantial risk for deep 
vein thrombosis and pulmonary embolism, and should 
perioperatively receive prophylactic high-dose molecular 
heparin as anticoagulation treatment  [53] .
 VIPoma 
 In VIPoma patients, secretory diarrhea is generally ex-
tensive, with severe loss of potassium and bicarbonate 
leading to metabolic acidosis, dehydration, and hypoka-
lemia  [52] . Patients need to be resuscitated from life-
threatening fluid losses and electrolyte abnormalities 
with somatostatin analog treatment, as well as intrave-
nous and electrolyte therapy, before being subjected to 
surgery. 
 Syndromes Related to Ectopic Hormonal Secretion 
 Occasionally the substances secreted by gastrointesti-
nal NET are not directly related to the tissue of origin and 
the corresponding clinical syndromes are related to these 
ectopically secreted compounds  [54] . Appreciation of the 
presence of such syndromes is highly relevant, because if 
the clinical presentation is not identified, it may delay the 
diagnosis of the underlying neoplasia and lead to in-
creased morbidity and mortality. Some of these syn-
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dromes, such as Cushing syndrome due to ectopic adre-
nocorticotrophic hormone and hypercalcemia due to ec-
topic parathyroid hormone-related peptide secretion, 
may markedly increase the operative risk and need to be 
adequately treated prior to any intervention  [54] . In pa-
tients with uncontrolled hormonal syndrome due to ec-
topic hormone secretion, hepatic artery embolization or 
chemoembolization and/or debulking surgery can be dis-
cussed.
 Adrenocorticotrophic hormone secretion leading to 
Cushing syndrome has mostly been encountered with 
lung NET, but can occasionally be seen with gastrointes-
tinal tumors  [54, 55] . Drugs aiming at controlling the 
hormonal secretion, either at the tumor level (soma-
tostatin analogs, cabergoline), the adrenals (metyra-
pone, ketoconazole, O,p ′ -DDD) or rarely the glucocor-
ticoid receptor, markedly reduce the operative risk, 
which may be considerably high if the hypercortisolism 
remains untreated  [56] . In refractory cases, intravenous 
etomidate has successfully been used but requires inten-
sive monitoring  [57] . Hypersecretion of parathyroid 
hormone-related peptide by metastatic NET seems to be 
exclusively associated with metastatic pancreatic NET 
and has a major clinical impact because poorly control-
lable hypercalcemia is associated with increased mor-
bidity and mortality  [58] . In such cases and other more 
rare syndromes, early diagnosis and management are es-
sential  [54] .
 Minimal Consensus Statement on Preoperative 
Evaluation and Therapy 
 Preoperatively, patients with NET and carcinoid syn-
drome need to be carefully evaluated. Patients with se-
vere diarrhea, weight loss, vitamin deficiencies, and hy-
poproteinemia require parenteral nutrition and ade-
quate supplementation for reversal of fluid, electrolyte, 
vitamin and protein abnormalities, before major surgery 
is undertaken. Patients with carcinoid syndrome should 
be examined with echocardiography and NT-proBNP 
measurement to diagnose the possible presence of incip-
ient CHD prior to abdominal surgery. Even patients with 
moderate CHD should be discussed with cardiologists 
before surgery as symptoms may be absent in a signifi-
cant number of patients. In case of significant heart dis-
ease, a thoracic surgical evaluation and possible surgical 
revision of valvular heart disease should be considered 
before major abdominal operation, especially liver resec-
tion, is undertaken.
 Minimal Consensus Statement on Perioperative 
Prophylaxis and Treatment to Prevent Carcinoid 
Crisis 
 Patients with carcinoid syndrome should receive oc-
treotide prophylaxis to prevent the development of carci-
noid crisis during surgery. Patients with CHD and/or 
high 5-HIAA levels are at higher risk. If patients already 
receive octreotide or other somatostatin analogs, this 
medication should be continued while awaiting surgery. 
Patients who have not received octreotide can be given 
100–200 μg 3 times/day subcutaneously for 2 weeks prior 
to surgery. If more acute operation is needed, octreotide 
is given as an intravenous infusion for 1–2 days before 
surgery. Perioperative treatment is recommended with 
intravenous octreotide; infusion is started 12 h before an-
esthesia at a dose of 50–100 μg/h using dose titration un-
til resolution of the symptoms (mean dose 100–200 μg/h). 
Remaining symptoms of carcinoid syndrome indicate the 
need for additional intravenous octreotide. In case of a 
carcinoid crisis reaction with hypotension during anes-
thesia, adrenergic drugs should be used cautiously and 
further octreotide infusion should be given even at doses 
as high as 500 μg/h. Patients previously treated with so-
matostatin analogs may require even higher doses.
 Minimal Consensus Statement on Recommendation 
Concerning Anesthesia 
 Monitoring of central venous pressure is of value dur-
ing surgery for NET with carcinoid syndrome, but may 
be difficult to interpret in the presence of CHD with right-
sided failure. Preoperative medication and anesthesia 
should exclude drugs that may stimulate the sympathetic 
system or cause histamine release. If hypotension occurs, 
sympathomimetic drugs should be used cautiously, and 
increased intravenous octreotide should be given. Hypo-
tension is treated by the prevention of peptide release 
with octreotide, and by increasing the depth of anesthe-
sia. In the presence of bronchospasm, β-receptor agonists 
should be used with great care or, instead, octreotide is 
recommended, possibly together with steroids (dexa-
methasone). Flushing during anesthesia should consti-
tute a warning of cardiovascular instability and indicates 
increased requirement of octreotide. Preoperative treat-
ment with octreotide should continue and be weaned 
slowly over the first postoperative week rather than 
abruptly stopped. Hypovolemia and pain-causing sym-
pathetic stimulation should be avoided in the postopera-
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tive period. Non-histamine-releasing opioids such as fen-
tanyl have been used with no adverse effects for postop-
erative analgesia.
 Minimal Consensus Statement on Pre- and 
Perioperative Management of Pancreaticoduodenal 
NET 
 Patients with gastrinoma require treatment with a ti-
trated dose of PPIs before, during and few weeks after the 
operation to be protected from hypersecretion. Insulino-
ma patients should be subjected to careful glucose moni-
toring during and after surgery. Patients with glucagono-
ma require somatostatin analog treatment and nutrition-
al supplementation to heal the skin lesion prior to surgery, 
and perioperative anticoagulation to prevent thrombosis. 
Patients with VIPoma need to be resuscitated with pre-
operative somatostatin analog treatment and intravenous 
fluid and electrolyte therapy before being subjected to 
surgery. A high index of suspicion is required to identify 
syndromes related to ectopic hormonal secretion prior to 
surgery and initiate appropriate treatment. 
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